Halozyme Therapeutics, Inc. $HALO Shares Sold by Shelton Wealth Management LLC

Shelton Wealth Management LLC lowered its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 25.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,686 shares of the biopharmaceutical company’s stock after selling 5,371 shares during the period. Shelton Wealth Management LLC’s holdings in Halozyme Therapeutics were worth $1,732,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. MidFirst Bank bought a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at about $27,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Halozyme Therapeutics in the second quarter worth about $28,000. Quantbot Technologies LP bought a new position in Halozyme Therapeutics in the second quarter worth about $30,000. CoreCap Advisors LLC lifted its holdings in Halozyme Therapeutics by 98.0% in the third quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 150 shares during the period. Finally, Caitlin John LLC purchased a new stake in Halozyme Therapeutics in the second quarter worth about $44,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Up 0.3%

Shares of NASDAQ:HALO traded up $0.33 during midday trading on Friday, reaching $121.84. The company’s stock had a trading volume of 2,082,309 shares, compared to its average volume of 2,921,217. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The firm has a 50 day moving average of $109.06 and a 200-day moving average of $84.92. The firm has a market capitalization of $13.83 billion, a P/E ratio of 36.37, a PEG ratio of 0.46 and a beta of 0.88. Halozyme Therapeutics, Inc. has a 12-month low of $61.22 and a 12-month high of $122.45.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company had revenue of $481.00 million during the quarter, compared to analysts’ expectations of $402.28 million. During the same period last year, the company posted $1.54 EPS. Halozyme Therapeutics’s revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, research analysts anticipate that Halozyme Therapeutics, Inc. will post 8.31 earnings per share for the current year.

Halozyme Therapeutics News Summary

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks upgraded HALO from “hold” to “strong buy,” citing strong price performance and favorable earnings trends. The upgrade helped reinforce investor momentum. 5 Stocks to Buy Using the Relative Price Strength Strategy
• Positive Sentiment: H.C. Wainwright reaffirmed its Buy rating on Halozyme, signaling continued confidence in the company’s growth outlook and commercial execution. H.C. Wainwright Reaffirms Their Buy Rating on Halozyme
• Positive Sentiment: TD Cowen projected substantial price appreciation for HALO, adding to the positive analyst sentiment surrounding the stock. TD Cowen Forecasts Strong Price Appreciation for Halozyme
• Positive Sentiment: Halozyme was highlighted in multiple stock-selection reports as a relative-strength and top-ranked nontechnology Nasdaq pick, based on strong price performance and rising earnings estimates. Buy 5 Top-Ranked Non-Tech Nasdaq Stocks
• Neutral Sentiment: An expanded agreement with argenx could improve Halozyme’s long-term royalty and licensing opportunity, but investors are weighing the deal’s ultimate financial contribution and execution risks. Is Expanded Argenx Deal Altering the Investment Case for Halozyme?

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 1,626 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the sale, the director directly owned 40,418 shares of the company’s stock, valued at $4,154,970.40. The trade was a 3.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total value of $2,148,600.00. Following the completion of the sale, the chief executive officer owned 767,780 shares in the company, valued at $82,482,605.40. The trade was a 2.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 125,852 shares of company stock valued at $13,538,046. Corporate insiders own 2.50% of the company’s stock.

Analyst Upgrades and Downgrades

HALO has been the topic of several research reports. Citizens Jmp lifted their price objective on Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a research report on Friday, August 7th. Wells Fargo & Company increased their target price on Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $83.00 to $110.00 in a research report on Friday, August 7th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Finally, Stifel Nicolaus set a $130.00 price target on Halozyme Therapeutics in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $99.55.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.